Cellectar shareholders approve warrant exercise for up to 39.6M shares, increase share reserve by 2M

Cellectar Biosciences, Inc.

Class III directors Andrew Gu and Douglas J. Swirsky elected to three-year terms.
Shareholders approved 2,000,000 share increase under 2021 Stock Incentive Plan.
Shareholders approved exercise of warrants for up to 39,618,078 shares of common stock.
Deloitte & Touche ratified as independent auditor for fiscal year 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.